Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Inclusion Criteria:

- Male or female patients ≥18 years of age

- Patients with solid tumours who have received at least one line of therapy for
advanced disease

- Measurable or non-measurable evaluable disease per RECIST 1.1

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤1

- Standard of care and/or any investigational therapies must have been completed at
least 3 weeks prior to treatment

Exclusion Criteria:

- Prior malignancy within the previous 2 years except for locally curable cancers that
have been cured, such as basal or squamous cell skin cancer, or carcinoma in situ of
the cervix, breast or bladder

- Known primary central malignancy or symptomatic central nervous system metastasis

- Major surgical intervention within 28 days before study drug administration

- Significant acute or chronic infections